Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors

NeuroImmunoModulation

Volumn 16, Issue 6, 2009, Pages 385-391

  Reske, Dirk ^a   Thomas, Anne V ^a   Petereit, Hela Felicitas ^b   Fink, Gereon R ^a   Schroeter, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Heilig Geist Krankenhaus Koln   (Germany)

Author keywords

Cytokine production; Glatiramer acetate; IL12p40; Interferon; Intravenous immunoglobulins; Multiple sclerosis

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12P40; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; LEUKOCYTE COUNT; LEUKOCYTE CULTURE; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; BLOOD DONORS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12 SUBUNIT P40; LEUKOCYTES; MALE; MONOCYTES; MULTIPLE SCLEROSIS; PEPTIDES; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650495227     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228913     Document Type: Article

References (13)

1. Link J: Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. Acta Neurol Scand Suppl 1994;158:1-58.
2. Navikas V, Link H: Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996;15:322-333. (Pubitemid 26299587)
3. Petereit HF, Reske D, Pukrop R, Maas-Enriquez M, Japp G, Jongen PJ, Kölmel HW, Merkelbach S, Hartung HP, Heiss WD, Hommes OR: No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis. Mult Scler 2006;12:66-71. (Pubitemid 43169239)
4. Rohowsky-Kochan C, Molinaro D, Cook SD: Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Mult Scler 2000;6:69-77. (Pubitemid 30218898)
5. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, Wekerle H, Hohlfeld R: Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000;97:7452-7457. (Pubitemid 30431484)
6. Petereit HF, Bamborschke S, Esse AD, Heiss WD: Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis. Mult Scler 1997;3:180-183.
7. Coclet-Ninin J, Dayer JM, Burger D: Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 1997;8:345-349. (Pubitemid 28031321)
8. Reske D, Schoppe S, Broicher C, Petereit HF: The immunomodulatory properties of in vitro immunoglobulins are dose-dependent. Acta Neurol Scand 2003;108:267-273. (Pubitemid 37153533)
9. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589-593.
10. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen VA, Lee ML: Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-1281. (Pubitemid 28240339)
11. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Lüer W, Helwig A, Poser S: Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
12. Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group: Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008;71:265-271.
13. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E: Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009;15:50-58.